HROW
Harrow Health Inc
NASDAQ: HROW · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$35.90
+7.29% today
Updated 2026-06-10
Market cap
$1.31B
P/E ratio
—
P/S ratio
4.89x
EPS (TTM)
$-0.38
Dividend yield
—
52W range
$28 – $55
Volume
0.7M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.7
Growth
C4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
0.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →209 stocks currently score above 75
Price targets
Analyst target
$67.75
+88.72%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z 0.89 — distress zone
- Thin margins at -5.57%
- Negative free cash flow $-9.19M
- Revenue declining -7.60% QoQ
- Debt/equity 10.47x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $88.59M | $130.19M | $199.61M | $272.30M | $268.68M |
| Net income | $-14.09M | $-24.41M | $-17.48M | $-5.14M | $-27.60M |
| EPS | — | — | — | — | $-0.38 |
| Free cash flow | $-6.07M | $-148.71M | $-60.88M | $42.98M | $-9.19M |
| Profit margin | -15.90% | -18.75% | -8.76% | -1.89% | -5.57% |
Peer comparison
Smart narrative
Harrow Health Inc trades at $35.90. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.89, it sits in the distress. TTM revenue stands at $268.68M. with profit margins at -5.57%.
Frequently asked questions
What is Harrow Health Inc's stock price?
Harrow Health Inc (HROW) trades at $35.90, on a P/S of 4.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Harrow Health Inc overvalued?
Harrow Health Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Harrow Health Inc (HROW)?
The 12-month analyst consensus target is $67.75, about 88.7% above the current $35.90. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Harrow Health Inc's revenue?
Harrow Health Inc's trailing twelve-month revenue is $268.68M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Harrow Health Inc's Altman Z-Score is 0.89, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.89x
ROE-35.40%
Beta0.34
50D MA$36.28
200D MA$41.34
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—